Placebos in clinical practice and research

Journal of Medical Ethics

Volumn 22, Issue 3, 1996, Pages 140-146

  De Deyn, P P ^a   D'Hooge, R ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NONE   (Belgium)

Author keywords

Alzheimer's disease; Deontology; Epilepsy; Medical ethics; Placebo; Research

Indexed keywords

PLACEBO;

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFLICT; DIAGNOSTIC APPROACH ROUTE; INFORMED CONSENT; MEDICAL ETHICS; NEUROPSYCHIATRY; RISK ASSESSMENT; THERAPY;

EID: 0029938633     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.22.3.140     Document Type: Article

References (40)

1. Shapiro AK. Factors contributing to the placebo effect. Their implications for psychotherapy. American Journal of Psychotherapy 1961; 18: 73-88.
2. Delay J, Pichot P. Medizinische Psychologie. Stuttgart. Thieme, 1973.
3. Battezzati M, Tagliaferro A, de Marchi G. La legatura delle due arterie mammarie interne nei disturbi di vascolarizzazione del miocardio: nota preventiva relative de primi dati sperimentali e clinici. Minerva Medica 1995; 46: 1178-88.
4. Ratcliff JD. New surgery for ailing hearts. Reader's Digest 1957; 71: 70-3.
5. Brill IC, Rosenbaum WM, Rosenbaum EE, Flanery JR. Internal mammary artery ligation. Northwest Medicine 1958; 57: 483-6.
6. Harken DE Clinical conference: long-term management of patients with coronary artery disease. Circulation 1958; 17: 945-52.
7. Kitchell JR, Glover RP, Kyle RH. Bilateral internal mammary artery ligation for angina pectoris. American Journal of Cardiology 1958; 1: 46-50.
8. Cobb LA, Thomas GI, Dillard DH, et al. An evaluation of internal-mammary-artery ligation by a double-blind technique. New England Journal of Medicine 1959; 260: 1115-8.
9. Diamond EG, Kittle CF, Crockett JE. Evaluation of internal mammary artery ligation and sham procedure in angina pectoris. Circulation 1958; 18: 712-3.
10. Leber P. Is there an alternative to the randomized controlled trial? Psychopharmacology Bulletin 1991, 27: 3-8.
11. Lasagna L. Testimony given at Hearings before the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, United States Senate, 87th Congress, 1 st Session S. Res 52 on S. 1961; 1552: Part 1: 282-3.
12. Leber PD. The implicit assumptions of active control trials (a critical examination). Controlled Clinical Trials 1983; 14: 133.
13. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989; 30: S1: 57-63.
14. Park LC, Covi L. Nonblind placebo trial. An exploration of neurotic patients' responses to placebo when its inert content is disclosed. Archives of General Psychiatry 1965; 12: 336-45.
15. Elander G. Ethical conflicts in placebo treatment. Journal of Advanced Nursing 1991; 16: 947-51.
16. Goodwin JS, Goodwin JM, Vogel AV. Knowledge and use of placebos by house officers and nurses. Annals of Internal Medicine 1979; 91: 106-10.
17. Lasagna L, Masteller F, von Felsinger JM, Beecher HK. A study of the placebo response. American Journal of Medicine 1954; 16: 770-9.
18. Brewin TB. Consent to randomised treatment. Lancet 1982; ii: 919-21.
19. Levine RJ. The apparent incompatibility between informed consent and placebo-controlled clinical trials. Clinical Pharmacology and Therapy 1987; 42: 247-9.
20. Stanley B. Informed consent in treatment and research. In: Weiner JB, Hess AK, eds. Handbook of Forensic Psychology. New York: John Wiley & Sons, 1987: 63-85.
21. Pope K. FDA chief answers critics. Academic Focus 1992; 28: 28a-d.
22. Schönhöfer PS, Schulte-Sasse H, Manhold C, Werner B. Sind Extrade aus den Blättern des Ginkgobaumes bei peripheren Durchblutungs- und Hirnleistungsstörungen im Alter wirksam? Beurteilung von Tebonin und Rökan. Internal Praxis 1989; 29: 585-601.
23. Schönhöfer PS. Ginkgo biloba extracts. Lancet 1990; 1: 788
24. Kleijnen J, Knipschild P Ginkgo biloba. Lancet 1992; 340: 1136-9.
25. Kimbel KH. Ginkgo biloba. Lancet 1992; 340: 1474.
26. Brown WA. Predictors of placebo response in depression, Psychopharmacology Bulletin 1988; 24: 14-7.
27. Quitkin FM, Rabkin JG, Stewart JW, et al. Heterogeneity of clinical response during placebo treatment. American Journal of Psychiatry 1991; 148: 193-6.
28. Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology 1994; 10: 265-9.
29. Curson DA, Hirsch SR, Platt SD, et al. Does short term placebo treatment of chronic schizophrenia produce long term harm? British Medical Journal 1986; 293: 726-8.
30. Meinardi H. Clinical evaluation of antiepileptic drugs: Guidelines of the International League Against Epilepsy. In: De Deyn PP, D'Hooge R, Schafer A, eds. The ethics of animal and human experimentation. London: John Libbey, 1994: 279-85.
31. Theodore WH, Rauberras RF, Porter RJ. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991; 32: 392-7.
32. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex partial seizures. Journal of Neurology, Neurosurgery and Psychiatry 1982; 45: 1119-24.
33. Gram L, Schmidt D. Innovative designs of controlled clinical trials in epilepsy. Epilepsia 1993; 34 S7: 1-6.
34. Bourgeois B, Leppik JF, Sackellares JC. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43: 693-6.
35. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991; 32: 716-21.
36. Elwes RDC, Johnson AL, Reynolds EM. The course of untreatable epilepsy. British Medical Journal 1988; 297: 948-50.
37. Beghi L, Tognoni G. Prognosis of epilepsy in newly referred patients: a multicentre prospective study. Epilepsia 1988; 29: 236-43.
38. Reynolds EH. The influence of antiepileptic drugs on the natural history of epilepsy. Epilepsy Research 1991; S3: 15-20.
39. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer's disease. Journal of the American Medical Association 1994; 271: 985-91.
40. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association 1994; 271: 992-8.